600521 华海药业
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入4,912,8258.78%8,587,1469,547,4258,308,7208,265,745
减:营业总成本4,348,0748.66%8,145,9057,978,7397,096,9006,635,694
    其中:营业成本2,043,43923.36%3,421,5133,636,6043,288,3383,110,936
               财务费用204,819109.88%248,16195,480137,247(10,833)
               资产减值损失(18,906)-65.18%(205,464)(122,874)(117,176)(70,604)
公允价值变动收益9,596-70.65%48,740(69,493)(100,248)5,201
投资收益211,125-1,845.60%18,800(28,720)(62,652)(75,205)
    其中:对联营企业和合营企业的投资收益(35,896)218.36%(18,750)(28,660)(27,700)(42,191)
营业利润854,33157.84%456,4611,470,7891,124,5401,547,171
利润总额902,03566.16%443,8771,463,6081,100,3211,508,900
减:所得税费用134,947-2.00%216,548356,145283,072332,890
净利润767,08889.33%227,3291,107,463817,2491,176,009
减:非控股权益(3,822)-11.71%(39,070)(11,518)(13,217)8,251
股东净利润770,91088.26%266,3991,118,981830,4661,167,759

市场价值指针
每股收益 (元) *0.52085.71%0.1800.7700.5700.810
每股派息 (元) *----0.1000.2500.2000.240
每股净资产 (元) *6.371-1.36%6.1465.9035.2864.925
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容